Cytotoxic effects toward human hematopoietic progenitor cells and tumor cell lines of paclitaxel, docetaxel, and newly developed analogues IDN5109, IDN5111, and IDN5127

Oncology Research

Volumn 11, Issue 10, 1999, Pages 471-478

  Ferlini, Cristiano ^a   Distefano, Mariagrazia ^a   Pierelli, Luca ^a   Bonanno, Giuseppina ^a   Riva, Antonella ^b   Bombardelli, Ezio ^b   Ojima, Iwao ^c   Mancuso, Salvatore ^a   Scambia, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b INDENA S P A   (Italy)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Cell cycle block; Docetaxel; Hematopoietic progenitors; Paclitaxel; Taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; CD34 ANTIGEN; DOCETAXEL; DRUG DERIVATIVE; IDN 5111; ORTATAXEL; PACLITAXEL; TAXOID;

ARTICLE; CELL CULTURE; CELL CYCLE; CELL DIVISION; CHEMISTRY; DRUG EFFECT; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; IC 50; METABOLISM; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; TIME;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRIDGED COMPOUNDS; CELL CYCLE; CELL DIVISION; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; PACLITAXEL; TAXOIDS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0033288802     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667; 1979.
2. Vasey, P. A.; Jones, N. A.; Jenkins, S.; Dive, C.; Brown, R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol. Pharmacol. 50:1536-1540; 1996.
3. Righetli, S. C.; Della, T. G.; Pilotti, S.; Menard, S.; Ottone, F.; Colnaghi, M. I.; Pierotti, M. A.; Lavarino, C.; Comarotti, M.; Oriana, S.; Bohm, S.; Bresciani, G. L.; Spatti, G.; Zunino, F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56:689-693; 1996.
4. Ravdin, P. M. Taxoids: Effective agents in anthracycline-resistant breast cancer. Semin. Oncol. 22:29-34; 1995.
5. Burris, H. A.; Fields, S.; Peacock, N. Docetaxel (Taxotere) in combination: A step forward. Semin. Oncol. 22:35-40; 1995.
6. Bhalla, K.; Huang, Y.; Tang, C.; Self, S.; Ray, S.; Mahoney, M. E.; Ponnathpur, V.; Tourkina, E.; Ibrado, A. M.; Bullock, G.; Willingham, M. C. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 8:465-475; 1994.
7. Pazdur, R.; Lassere, Y.; Soh, L. T.; Ajani, J. A.; Bready, B.; Soo, E.; Sugarman, S.; Patt, Y.; Abbruzzese, J. L.; Levin, B. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann. Oncol. 5:468-470; 1994.
8. Smeets, M.; Raymakers, R.; Vierwinden, G.; Pennings, A.; van-de-Locht, L.; Wessels, H.; Boezeman, J.; de-Witte, T. A low but functionally significant MDRI expression protects primitive haemopoietic progenitor cells from anthracycline toxicity. Br. J. Haematol. 96:346-355; 1997.
9. Uchida, N.; Combs, J.; Chen, S.; Zanjani, E; Huffman, R.; Tsukamoto, A. Primitive human hematopoietic cells displaying differential efflux of the rhodamine 123 dye have distinct biological activities. Blood 88:1297-1305; 1996.
10. Ojima, I.; Slater, J. C; Michaud, E.; Kuduk, S. D.; Bounaud, P. Y.; Vrignaud, P.; Bissery, M. C.; Veith, J. M.; Pera, P.; Bernacki, R. J. Syntheses and structure-activity relationships of the second-generation antitumor taxoids: Exceptional activity against drug-resistant cancer cells. J. Med. Chem. 39:3889-3896; 1996.
11. Distefano, M.; Scambia, G.; Ferlini, C.; Gaggini, C.; De-Vincenzo, R.; Riva, A.; Bombardelli, E.; Ojima, I.; Fattorossi, A.; Panici, P. B.; Mancuso, S. Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on mullidrug-resistance-positive human cancer cells. Int. J. Cancer 72:844-850; 1997.
12. Scambia, G.; Ranelletti, F. O.; Panici, P. B.; De-Vincenzo, R.; Bonanno, G.; Ferrandina, G.; Piantelli, M.; Bussa, S.; Rumi, C.; Cianfriglia, M.; Mancuso, S. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother. Pharmacol. 34:459-464; 1994.
13. Pierelli, L.; Iacone, A.; Quaglietta, A. M.; Nicolucci, A.; Menichella, G.; Benedetti, P. P.; D'Antonio, D.; De-Laurenzi, A.; De-Rosa, L.; Fioritoni, G.; Indovina, A.; Leone, G.; Majolino, I.; Montuoro, A.; Scime, R. Haemopoietic reconstitution after autologous blood stem cell transplantation in patients with malignancies: A multicentre retrospective study. Br. J. Haematol. 86:70-75; 1994.
14. Pierelli, L.; Scambia, G.; d'Onofrio, G.; Ciarli, M.; Fattorossi, A.; Bonanno, G.; Menichella, G.; Battaglia, A.; Benedetti, P. P.; Tommasi, M.; Mancuso, S.; Leone, G. Generation of multinuclear tartrate-resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34+ progenitors. Br. J. Haematol. 96:64-69; 1997.
15. Ferlini, C.; Di-Cesare, S.; Rainaldi, G.; Malorni, W.; Samoggia, P.; Biselli, R.; Fattorossi, A. Flow cytometric analysis of the early phases of apoptosis by cellular and nuclear techniques. Cytometry 24:106-115; 1996.
16. Motulsky, H. J.; Ransnas, L. A. Fitting curves to data using nonlinear regression: A practical and nonmathematical review. FASEB J. 1:365-374; 1987.
17. Ferlini, C.; Scambia, G.; Distefano, M.; Filippini, P.; Isola, G.; Riva, A.; Bombardelli, E.; Fattorossi, A.; Benedetti, P. P.; Mancuso, S. Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Br. J. Cancer 75:884-891; 1997.
18. Valero, V. Treatment of patients resistant to paclitaxel therapy. Anticancer Drugs 7(Suppl. 2):17-19; 1996.
19. Verweij, J.; Clavel, M.; Chevalier, B. Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. Ann. Oncol. 5:495-505; 1994.
20. Brown, J. M.; Wouters, B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1391-1399; 1999.